Download PDF
Thromb Haemost 1976; 36(03): 517-524
DOI: 10.1055/s-0038-1648071
Original Article
Schattauer GmbH

Prothrombin Determination by Means of a Chromogenic Peptide Substrate

G Axelsson
1   Department of Medicine II, Department of Clinical Chemistry, University of Göteborg, Sahlgren’s Hospital, S-413 45 Göteborg, Sweden
,
K Korsan-Bengtsen
1   Department of Medicine II, Department of Clinical Chemistry, University of Göteborg, Sahlgren’s Hospital, S-413 45 Göteborg, Sweden
,
J Waldenström
1   Department of Medicine II, Department of Clinical Chemistry, University of Göteborg, Sahlgren’s Hospital, S-413 45 Göteborg, Sweden
› Author Affiliations
Further Information

Publication History

Received 04 January 1976

Accepted 24 June 1976

Publication Date:
03 July 2018 (online)

    Permissions and Reprints

Summary

A two stage method to determine prothrombin with the chromogenic peptide substrate benzoyl-phe-val-arg-p-nitroanilide has been worked out. Citrated plasma (10 μl) was diluted in 600 μl tris buffer, pH 8.2, ionic strength 0.18 and activated with 250 μl of a commercial rabbit brain-lung thromboplastin. After 325 s incubation at 37° C 200 μl of a 1 mM solution of the chromogenic substrate was added and the increase in absorbance was recorded in a LKB-Beckman 8600 enzyme analyzer. A reading time of 1 minute (including a delay of 20 s) was used which permitted 55 analyses per hour to be carried out. An approximate linear relationship was found between ΔA/min and dilutions of normal plasma in prothrombin deficient plasma. The method is insensitive to variations of factors V, VII and X. Less than 10 % of normal plasma was needed to “normalize” plasmas deficient in factor V or VII or X.

A group of 99 dicoumarol treated patients and 23 normal subjects has been investigated using the present method and compared with a factor II-VII-X determination method. A correlation coefficient of 0.95 was found.

 

  • References

  • 1 Bergström K, Blombäck M. 1974; Determination of plasma prothrombin with a reaction rate analyzer using a synthetic substrate. Thrombosis Research 4: 719.
    CrossrefPubMedGoogle Scholar
  • 2 Bergström K, Lahnborg G. 1975; The effect of major surgery, low doses of heparin and thromboembolism on plasma antithrombin. Comparison of immediate thrombin inhibiting capacity and the antithrombin III content. Thrombosis Research 6: 223.
    CrossrefPubMedGoogle Scholar
  • 3 Blombäck M, Blombäck B, Olsson P, Svendsen L. 1974; The assay of antithrombin using a synthetic cromogenic substrate for thrombin. Thrombosis Research 5: 621.
    CrossrefPubMedGoogle Scholar
  • 4 Korsan-Bengtsen K. 1970; Comparison between various methods used to control dicoumarol therapy. Acta Medica Scandinavia 188: 327.
    PubMedGoogle Scholar
  • 5 Svendsen L, Blombäck B, Olsson P. 1972; Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thrombosis Research 1: 267.
    CrossrefPubMedGoogle Scholar
  • 6 Odegård O. R, Lie M, Abildgaard U. 1975; Heparin cofactor activity measured with an amidolytic method. Thrombosis Research 6: 287.
    CrossrefPubMedGoogle Scholar